➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Medtronic
Johnson and Johnson
Colorcon
McKesson

Last Updated: May 12, 2021

DrugPatentWatch Database Preview

LUSEDRA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Lusedra patents expire, and what generic alternatives are available?

Lusedra is a drug marketed by Eisai Inc and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-four patent family members in twenty-five countries.

The generic ingredient in LUSEDRA is fospropofol disodium. Additional details are available on the fospropofol disodium profile page.

DrugPatentWatch® Generic Entry Outlook for Lusedra

Lusedra was eligible for patent challenges on December 12, 2012.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 1, 2022. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Get Started for $10

Summary for LUSEDRA
International Patents:34
US Patents:1
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 17
Clinical Trials: 8
DailyMed Link:LUSEDRA at DailyMed
Drug patent expirations by year for LUSEDRA
DrugPatentWatch® Estimated Generic Entry Opportunity Date for LUSEDRA
Generic Entry Date for LUSEDRA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LUSEDRA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Grace Shih, MDN/A
Mayo ClinicPhase 4
Eisai Inc.Phase 1

See all LUSEDRA clinical trials

US Patents and Regulatory Information for LUSEDRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc LUSEDRA fospropofol disodium SOLUTION;INTRAVENOUS 022244-001 Dec 12, 2008 DISCN No No   Get Started for $10   Get Started for $10 Y Y   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Moodys
Merck
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.